Alnylam CEO Granted $18M Performance Award with Aggressive $500+ Price Targets
ALNYLAM PHARMACEUTICALS, INC.
Subscribe to track ALNY
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Alnylam CEO Granted $18M Performance Award with Aggressive $500+ Price Targets
Company: Alnylam Pharmaceuticals, Inc. (ALNY) Form: 8-K | Filed: 2026-03-04 Significance: Low (0.04% of Market Cap)
Insider: Yvonne Greenstreet Title: Chief Executive Officer | Relationship: Officer
Transaction: • Type: Grant (Special Performance Award) • Shares: 55,373 (Target PSUs) • Price: $325.07 (Grant Date Fair Value) • Value: $18,000,000 • Vesting: Contingent on stock price reaching $500-$800
Key Insight: CEO incentives heavily aligned with shareholder value; awards only vest if stock appreciates 54-146% from current levels ($500-$800/share) by 2029.
Market Context: Grant aligns with "Alnylam 2030" growth goals. Transaction size is small relative to $44B market cap but signals strong board confidence.
Comprehensive Analysis
SEC Filing Analysis: Alnylam Pharmaceuticals, Inc. (ALNY)
Executive Summary
- Trading Significance: Low (0.04% of Market Cap)
- Key Takeaway: CEO receives $18M special equity award that only vests if stock price hits aggressive targets between $500 and $800 (54-146% upside).
- Market Impact: Neutral to Positive Sentiment (Long-term confidence signal).
Company Information
| Field | Value |
|---|---|
| Company | Alnylam Pharmaceuticals, Inc. |
| Ticker Symbol | ALNY |
| CIK | 0001178670 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | Yvonne Greenstreet |
| CIK | Not specified in 8-K |
| Title/Position | Chief Executive Officer |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 8-K |
| Transaction Date | 2026-03-02 |
| Transaction Code | A (Grant) |
| Security Type | Performance Share Units (PSUs) |
| Shares Involved | 55,373 (Target) |
| Price Per Share | $325.07 (Grant Date Close) |
| Total Value | $18,000,000 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $18,000,000 |
| % of Market Cap | 0.04% |
| Shares Transacted | 55,373 |
| % of Shares Outstanding | 0.04% |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: With a market cap of $44.15B, an $18M grant is financially immaterial (<0.1%) but strategically significant for executive alignment.
- Dilution Impact: Negligible dilution (0.04% of 132.11M shares outstanding).
- Incentive Structure: The award requires the stock to reach a minimum of $500 (54% increase) to trigger any vesting, with max vesting at $800 (146% increase).
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: While the grant size is not market-moving, the aggressive performance hurdles ($500-$800) signal the Board's expectation of significant growth, which may support long-term sentiment.
Volume & Sentiment
- Expected Volume Impact: Minimal.
- Sentiment Indicator: Bullish (Long-term). The structure of the award implies internal confidence in achieving the "Alnylam 2030" aspirational goals.
Additional Context
Transaction Notes
- Vesting Conditions: 0% vests below $500/share. 50% at $500, 100% at $600, 150% at $700, 200% at $800.
- Measurement Period: 30-day average closing price in the 6 months prior to Dec 31, 2029.
- Strategic Goal: Designed to retain leadership through the next growth phase ending in 2030.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.